UCB U.S. News

14 New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

Nov

09 Advancing Rheumatic Disease Treatment

Jan

18 Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

May

23 First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

May

12 Recognizing the Less Common, but Equally Burdensome, Forms of Arthritis During Arthritis Awareness Month

May

25 UCB Statement on Non-Radiographic Axial Spondyloarthritis ICD-10 Sub-Category Update

Today, UCB issued the following statement from Jeffrey Stark, M.D., Head of U.S. Medical Immunology, on the recent update by the ICD-10 Coordination and Maintenance Committee to endorse the creation of a new sub-category (M45.A) for non-radiographic axial spondyloarthritis (nr-axSpA).

Categories

Archives

Nov

14

New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

Nov

09

Advancing Rheumatic Disease Treatment

Jan

18

Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

May

23

First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

May

12

Recognizing the Less Common, but Equally Burdensome, Forms of Arthritis During Arthritis Awareness Month

May

25

UCB Statement on Non-Radiographic Axial Spondyloarthritis ICD-10 Sub-Category Update

Choose a Country

UCB in the U.S.

Patients

Innovation

Disease Areas

Sustainability

Newsroom

Contact